We are building a Global Leader in the field of Repurposing Drugs for Orphan Diseases.
Our mission is to discover drugs for high unmet medical needs that will improve quality of life for patients with Rare Diseases.
We stand out by our ability to deliver high value products with relatively little cost in a short period of time, due to our model we reduce the risk of drug development.
SOM Biotech has a strong pipeline of products focused on CNS at preclinical and clinical stages.
NEWS & PRESS RELEASES
SOM Biotech invited at Chinese-Swiss Health Collaborations Forum
SOM Biotech was one of the companies invited to the Private Chinese-Swiss Investor Collaborations Forum […]
II Workshop sobre Transferencia del Conocimiento Científico en la Distrofia Muscular de Duchenne
La Compañía SOM Biotech estuvo presente en el II Workshop sobre Transferencia del Conocimiento Científico en la […]
SOM Biotech licenses its first product and expands to the United States
The med-tech biopharmaceutical company SOM Biotech, specializing in repurposing drugs to treat rare nervous system […]
SOM Biotech at the 2017 New York Venture Summit
SOM Biotech was selected to present at the 2017 New York Venture Summit in front […]
21st Summer School of the University of Barcelona
Dr. Raúl Insa, SOM Biotech CEO, was invited to the 21st Summer School of the University […]
9th Summer School on Medicines
Dr. Raúl Insa, SOM Biotech CEO, was the invited speaker at Closing Session of 9th […]
SOM Biotech closed €2M funding round and opens €10M Series A
SOM Biotech closed €2M funding round on January 2017 where 18 international investors from 10 […]
SOM Biotech at World Orphan Drug Congress USA 2017
SOM Biotech attended the World Orphan Drug Congress USA 2017 (WODC) hold in Washington, USA […]
SOM Biotech at BIO Convention 2017
SOM Biotech attended last BIO Convention on June 19th-22nd 2017 in San Diego, CA. Michael […]
SOM Biotech takes part in the EU Compass program for Research Responsible Innovation (RRI)
SOM Biotech is one of the European companies participating in the EU Compass program, Biomedicine field. […]